December 2nd 2024
Your daily dose of the clinical news you may have missed.
November 27th 2024
A woman in her early 50s presents with 6 hours of right sided pleuritic chest pain. What do the history and ECG suggest? What's yoru Dx?
November 26th 2024
The patient shows no signs of trauma but is a poor historian so no further details are available. Do her vitals or ECG provide any clues to a Dx?
November 25th 2024
November 22nd 2024
New Data Suggest Atrial Fibrillation May be More Common in Younger Adults than Previously Thought
Patients with AF aged younger than 65 years have substantial comorbidity burden that may impact their future risk of mortality, reported researchers.
Maternal Vascular Indices, Biomarkers at 36 Week's Gestation Predict Preeclampsia, New Study Concludes
Increased arterial stiffness and elevated central BP are among factors researchers found to have strong discriminatory value for PE at term and postpartum.
After the CLEAR Outcomes Trial, ASCVD Risk Reduction Remains a Global Challenge, PI Nissen Says
The study that led to an historic expanded label for bempedoic acid must be followed by more like it, said Steven Nissen, MD. There is much more to do.
Bempedoic Acid Should be In Everyone's CVD Prevention Toolbox, According to Steven Nissen, MD
Statin intolerance is a "vexing" problem for primary care clinicians and specialists alike. Bempedoic acid fills a distinct need in that tool box.
Untreated, New-Onset Hypertension Tied to Higher Risk of Uterine Fibroids in Women
Women with new-onset HTN faced a 45% greater risk of newly self-reported fibroids and those with untreated HTN had a 19% greater risk, according to a new study.
Steven Nissen, MD, Discusses the "Sweet Spot" for Bempedoic Acid Among Non-Statin Therapies
The CLEAR Outcomes PI explains the patient selection approach for bempedoic acid, now approved to reduce risk of CV events in addition to lowering LDL-C.
8 Questions on Management of Chronic Coronary Disease: A Guideline Topline Quiz
Based on the updated 2023 AHA/ACC recommendations, the 9-question quiz tests what you know about the most current approaches to CCD treatment.
How the CLEAR Outcomes Trial Made CV Risk Reduction History, with Lead Investigator Steven Nissen, MD
Bempedoic acid became the first nonstatin LDL-C lowering medication indicated to reduce CV risk in both primary and secondary prevention. Nissen explains how.
Risk for CHD Higher for Women who Binge Drink vs Men: Daily Dose
New Research Suggests Cardiac Events are Prevalent in Older Adults Hospitalized with RSV
Nearly one-quarter of hospitalized adults aged 50 years and older with RSV experienced an acute cardiac event, according to results of a new study.
Elevated Lp(a) Level Increased ASCVD Risk Regardless of Age, Sex, Race/Ethnicity in Pooled Primary Prevention Cohort
Elevated lipoprotein(a) was independently associated with increased ASCVD risk across primary prevention subgroups including among those with LDL-C of 70 mg/dL.
Zilebesiran Reduces SBP on Background SOC in Uncontrolled HTN: Daily Dose
Triptans and Ischemic Events: A New Study Parses the Risk
Labeling for triptan medications warns of potential for ischemic events but is the concern theoretical or real? A new study tests the association.
Semaglutide Improves Functional Status, Body Weight in Patients with HFpEF, Obesity, T2D: Daily Dose
Management of Chronic Coronary Disease: A Guideline Topline in 10 Take-Home Messages
The 10 take-home points from the ACC/AHA cover diet, exercise, cardiac rehab, use of new treatments, reliance on statins, guidance on beta-blockers, plus more.
ADHD Stimulant Use Raises Risk of Cardiomyopathy in Young Adults: Daily Dose
Risk for CHD Double Among Women who Binge Drink vs Men
ACC.24: Even modest alcohol intake increases risk for coronary heart disease in men and women but women are at much greater risk across levels of weekly consumption.
Individuals with CVD Consume More Daily Sodium than Recommended, According to New Data
ACC.24: Adults with a history of CVD consumed more than double the recommended daily sodium amount, reported researchers.
Vaping Linked to Higher Risk of Heart Failure: Daily Dose
Novel Web Tool Determines Consumer Eligibility for OTC Statin, With High Clinician Concordance
The web app showed more than 90% concordance with clinical assessment of eligibility for low dose rosuvastatin; study yields 35.5% reduction in LDL-C.
Semaglutide 2.4 mg Improves Functional Status, Body Weight in Adults with HFpEF, Obesity, T2D
ACC.24: Results of STEP HFpEF DM showed significant improvement in quality of life measures among adults with obesity-related HFpEF and type 2 diabetes.
Zilebesiran Reduces SBP by Up to 14 mm Hg on Background SOC in Uncontrolled Hypertension: KARDIA-2
ACC.24: Zilebesiran led to clinically and statistically significant reductions in SBP on top of either a diuretic, CCB, or ARB; SQ dosing is every 3-6 months.
Secondary CVD Prevention Requires Much More than "Usual Care," Says Michael Koren, MD,
ACC.24: Individuals with ASCVD not at target LDL-C on maximum statin therapy need immediate intervention and one that works, said V-INITIATE primary investigator.
The Inclisiran Impact on PCSK9: A Primary Care Primer
ACC.24: Michael Koren, MD, highlights how the nonstatin lipid-lowering medication's mechanism of action against PCSK9 differs from others in the category.
Michael J Koren, MD, Reviews Success of "Inclisiran First" Strategy and Implications for Clinical Practice
ACC.24: The primary investigator of the VICTORION-INITIATE study explains why new strategies are needed to accelerate LDL-C lowering in high-risk individuals.
"Inclisiran First" Strategy Leads to 60% Reduction in LDL-C vs 7% for Usual Care: VICTORION-INITIATE Findings
ACC. 24: A structured, systematic approach to lipid-lowering therapy in secondary prevention is needed to ensure targets are met and met swiftly, said researchers.
Bempedoic Acid Reduces CV Risk in Latinx Population with Statin-Intolerance: Daily Dose
Optimal Cardioprotective BMI for Adults with Type 2 Diabetes Could Vary by Age, New Study Suggests
In a population cohort of adults with T2D, a BMI above "normal" range appeared more likely to protect against CV death in those older than age 65 years than those younger.
T2D Remission via Lifestyle Intervention Reduces CVD, CKD Risk: Daily Dose
Nontraditional Risk Factors More Likely to Cause Stroke in Young Adults, Study Finds
Migraine was the most important nontraditional risk factor linked to stroke in adults aged 18 to 34 years and should be considered in evaluation for an event.